Harvard Bioscience Q4 Adj EPS $0.04 Misses $0.05 Estimate, Sales $28.15M Miss $29.11M Estimate
Portfolio Pulse from Benzinga Newsdesk
Harvard Bioscience reported Q4 adjusted EPS of $0.04, missing the consensus estimate of $0.05, and sales of $28.15M, missing the estimate of $29.11M. This represents a year-over-year decrease in sales.
March 07, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Harvard Bioscience missed Q4 earnings and sales estimates, with an adjusted EPS of $0.04 and sales of $28.15M.
Missing both earnings and sales estimates is generally viewed negatively by the market, likely leading to a short-term decrease in stock price. The year-over-year decrease in sales further compounds the negative outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100